125P - Comparison efficacy of preoperative chemotherapy and surgery with surgery alone in patients with stage IIIA non-small-cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Surgical Oncology
Non-Small Cell Lung Cancer
Biological Therapy
Radiation Oncology
Presenter Farrukh Djuraev
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors F. Djuraev1, R. Davidov2
  • 1Oncology, Tashkent Medical Academy, 100174 - Tashkent/UZ
  • 2Thoracical Oncology, City Oncology Centre, Tashkent/UZ



Improving survival in lung cancer is a major challenge for modern oncology. It is known that the efficacy of surgery for patients with non-small cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. By conducting our trial, we want to evaluate whether preoperative chemotherapy (PCT) could improve survival in resectable stage IIIA non-small-cell lung cancer (NSCLC).


We studied 46 patients (38 men and 8 woman) with stage IIIA non-small cell lung cancer. Trial was conducted in the department of thoracic oncology, Tashkent city oncological dispenser and retrospective analysis was performed for the periods from 2005 to 2010. The patients were randomly assigned to receive either surgery alone or three courses of chemotherapy (6 mg of mitomycin per square meter of bodysurface area, 3 g of ifosfamide per square meter, and 50 mg of cisplatin per square meter) given intravenously at three-week intervals and followed by surgery. Allpatients received mediastinal radiation after surgery.


Clinical response was 25% after 3 courses of chemotherapy. The median period of survival was 36 months in the patients treated with chemotherapy plus surgery, as compared with 9 months in the patients treated with surgery alone (P 


Results of our study showed that the chemotherapy followed by surgical treatment is more effective than surgery alone in patients with non-small cell lung cancer.

Clinical trial identification

Legal entity responsible for the study

Tahkent Medical Academy


Tashkent City Oncological Centre


All authors have declared no conflicts of interest.